These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 8761586)
1. Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis. Khalil EA; Nur NM; Zijlstra EE; El-Hassan AM; Davidson RN Trans R Soc Trop Med Hyg; 1996; 90(2):187-8. PubMed ID: 8761586 [No Abstract] [Full Text] [Related]
2. Combination of sodium stibogluconate and rifampicin in post kala-azar dermal leishmaniasis. Sharma VK; Prasad HR; Sethuraman G; Khaitan BK Indian J Dermatol Venereol Leprol; 2007; 73(1):53-4. PubMed ID: 17314452 [No Abstract] [Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal. Karki P; Koirala S; Parija SC; Sethi M; Das ML Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510 [TBL] [Abstract][Full Text] [Related]
5. Effects of itraconazole and terbinafine on Leishmania major lesions in BALB/c mice. Zakai HA; Zimmo SK Ann Trop Med Parasitol; 2000 Dec; 94(8):787-91. PubMed ID: 11214097 [TBL] [Abstract][Full Text] [Related]
6. Visceral leishmaniasis with concomittant post kala-azar dermal leishmaniasis responds to oral sitamaquine: case report. Mbui J; Rashid R; Lodenyo H; Nyakundi P; Kipmutai R; Mutuma G; Kirigi G; Kinoti D; Wasunna M East Afr Med J; 2003 Aug; 80(8):440-2. PubMed ID: 14601788 [TBL] [Abstract][Full Text] [Related]
7. Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report. Lindoso JAL; Moreira CHV; Celeste BJ; Oyafuso LKM; Folegatti PM; Zijlstra EE Rev Soc Bras Med Trop; 2018; 51(1):105-107. PubMed ID: 29513829 [TBL] [Abstract][Full Text] [Related]
8. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665 [TBL] [Abstract][Full Text] [Related]
10. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Kumar D; Ramesh V; Verma S; Ramam M; Salotra P Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997 [No Abstract] [Full Text] [Related]
11. A case of Post-kala-azar dermal leishmaniasis. Ono H; Ghoreishi M; Yokozeki H; Katayama I; Nishioka K J Dermatol; 1998 Feb; 25(2):118-20. PubMed ID: 9563280 [TBL] [Abstract][Full Text] [Related]
12. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis. Ramesh V; Ansari NA; Jain RK; Salotra P Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988 [No Abstract] [Full Text] [Related]
13. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report. Ramesh V; Avishek K; Sharma V; Salotra P Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012 [No Abstract] [Full Text] [Related]
14. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277 [TBL] [Abstract][Full Text] [Related]
15. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation. Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439 [No Abstract] [Full Text] [Related]
16. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Antinori S; Longhi E; Bestetti G; Piolini R; Acquaviva V; Foschi A; Trovati S; Parravicini C; Corbellino M; Meroni L Br J Dermatol; 2007 Nov; 157(5):1032-6. PubMed ID: 17854365 [TBL] [Abstract][Full Text] [Related]
17. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India. Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204 [TBL] [Abstract][Full Text] [Related]
18. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. el Hassan AM; Ghalib HW; Zijlstra EE; Eltoum IA; Satti M; Ali MS; Ali HM Trans R Soc Trop Med Hyg; 1992; 86(3):245-8. PubMed ID: 1329273 [TBL] [Abstract][Full Text] [Related]
19. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Gilad J; Borer A; Hallel-Halevy D; Riesenberg K; Alkan M; Schlaeffer F Isr Med Assoc J; 2001 Jun; 3(6):451-2. PubMed ID: 11433642 [No Abstract] [Full Text] [Related]
20. Treatment of post-kala-azar dermal leishmaniasis. Ramesh V Int J Dermatol; 1994 Mar; 33(3):153-6. PubMed ID: 8169009 [No Abstract] [Full Text] [Related] [Next] [New Search]